Department of Gastroenterology and Metabolism, Hiroshima University Hospital, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Department of Endoscopy, Hiroshima University Hospital, Hiroshima, Japan.
J Gastroenterol. 2017 Nov;52(11):1169-1179. doi: 10.1007/s00535-017-1318-1. Epub 2017 Feb 13.
We aimed to clarify the long-term outcomes of patients with T1 colorectal carcinoma (CRC) after endoscopic resection (ER) and surgical resection.
We examined T1 CRC patients treated during 1992-2008 and who had ≥5 years of follow-up. Patients who did not meet the curative criteria after ER according to the Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines were defined as "non-endoscopically curable" and classified into three groups: ER alone (Group A: 121 patients), additional surgery after ER (Group B: 238 patients), and surgical resection alone (Group C: 342 patients). Long-term outcomes and predictors of recurrence were analyzed.
Of the 882 patients with T1 CRC, 701 were non-endoscopically curable. Among these patients, recurrence and 5-year overall survival (OS) rates were 0.6 and 91.1%, respectively. In Groups A, B, and C, recurrence rates were 5.0, 5.5, and 3.8%, OS rates were 79.3, 92.4, and 91.5% (p < 0.01), and 5-year disease-free survival (DFS) rates were 98.1, 97.9, and 98.5%, respectively. Thirty-two patients experienced local recurrence or distant/lymph node metastasis (Group A: 6; Group B: 13; Group C: 13) and 14 patients died of primary CRC (Group A: 3; Group B: 7; Group C: 4). Age ≥65 years, protruded gross type, positive lymphatic invasion, and high budding grade were significant predictors of recurrence in non-endoscopically curable patients.
Our findings supported the JSCCR criteria for endoscopically curable T1 CRC. ER for T1 CRC did not worsen the clinical outcomes of patients who required additional surgical resection.
本研究旨在阐明内镜切除(ER)治疗后 T1 结直肠癌(CRC)患者的长期预后,并比较手术切除与单纯 ER 治疗的效果。
我们回顾性分析了 1992 年至 2008 年期间接受治疗且随访时间≥5 年的 T1 CRC 患者。根据日本结直肠癌学会(JSCCR)的内镜下治愈标准,将 ER 后未达到治愈标准的患者定义为“非内镜可治愈”,并分为三组:单纯 ER 治疗(A 组,121 例)、ER 后追加手术(B 组,238 例)和单纯手术切除(C 组,342 例)。分析三组患者的复发情况及影响预后的相关因素。
882 例 T1 CRC 患者中,701 例为非内镜可治愈患者。这些患者的复发率和 5 年总生存率(OS)分别为 0.6%和 91.1%。A、B、C 三组患者的复发率分别为 5.0%、5.5%和 3.8%,5 年 OS 率分别为 79.3%、92.4%和 91.5%(P<0.01),5 年无病生存率(DFS)率分别为 98.1%、97.9%和 98.5%。32 例患者发生局部复发或远处/淋巴结转移(A 组 6 例,B 组 13 例,C 组 13 例),14 例患者死于原发性 CRC(A 组 3 例,B 组 7 例,C 组 4 例)。非内镜可治愈患者中,年龄≥65 岁、隆起型大体类型、阳性淋巴管浸润和高芽生分级是影响复发的独立危险因素。
本研究支持 JSCCR 的内镜下治愈 T1 CRC 标准。对于需要追加手术的 T1 CRC 患者,ER 治疗并未影响其临床预后。